SEC Form 4 · accession 0001214659-17-003496
Anthera Pharmaceuticals Inc · ANTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul F Truex
Officer — Executive Chaiman · Director
Period of report
May 19, 2017
Accepted (ET)
May 19, 2017 · 8:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001316175
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $96.64 | May 19, 2017 | J | 1,369 | D | — | Feb 18, 2019 | Common Stock | 1,369 | 0 | D |
| Stock option (right to buy)F2 | $39.04 | May 19, 2017 | J | 84,376 | D | — | May 17, 2023 | Common Stock | 84,376 | 0 | D |
Explanation of responses
- F1On May 19, 2017, the reporting person and the Company agreed to cancel an outstanding stock option to purchase 1,369 shares of common stock dated February 18, 2009 (the "option"), which option was previously reported on a Form 4 filed with the SEC on February 23, 2010. 50% of the options were to vest monthly over four years beginning August 12, 2008 (the Vesting Start Date) and 50% of the options vested upon successful completion of milestones determined by the Board. The options were fully vested on August 12, 2012. The Option would expire on Feburary 18, 2019.
- F2On May 19, 2017, the reporting person and the Company agreed to cancel a stock option to purchase 84,376 shares of common stock dated May 17, 2013 (the "option"), which option was previously reported on a Form 4 filed with the SEC on May 21, 2013. This option was to vest annually over four years beginning March 25, 2013 (the Vesting Start Date). The Option would have completely vested on the fourth anniversary of the Vesting Start Date and would expire on May 17, 2023.